Aarti Industries Ltd · NSE:AARTIIND
Aarti Industries — Q4 FY2019 Earnings Presentation
17 slides from Aarti Industries's earnings presentation, May 22, 2019
Slide 1: Exchange filing cover letter
.@ffi{*,=, Ref. No.: AILIB-38 lzOL I 343 May 22,2OL9 To, To, Listing,/ ComPliance rtment Listing/ Compliance Department BSE LTD. National Stock Exchange of Phtroze Jeejeebhoy T India Limited Dalal Street, "Exchange Plaza" , Plot No. C I l, MumbeLi - 400 001. G Block Bandra-Kurla Complex, Bandra (E),
Slide 2: Q4 & FY19 Results Presentation
AARTI INDUSTRIES LIMITED Q4 & FY19 Results Presentation May 2019
Slide 3: Disclaimer
Disclaimer AARTI INDUSTRIES LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not
Slide 4: Agenda
Agenda 1 | At a glance 2 | Quarterly performance 3
Slide 5: Company Overview
Company Overview Overview Key Metrics A leading Speciality Chemicals company in Benzene based derivatives with integrated operations and high level of cost optimization Established by first generation technocrats in 1984 200+ 400+ 700+ Global Domestic Pharma operations spanning APIs, intermedi
Slide 6: Key Strengths
Key Strengths • Global Player in Benzene based Derivatives with Integrated Operations o Strong/Leadership position in key products and processes o Integrated operations across product chain of Benzene and Toluene o Ability to effectively use co‐products and generate value‐added products • Well Diver
Slide 7: Agenda
Agenda 1 | At a glance 2 | Quarterly performance 6
Slide 8: Chairman's Message
Chairman’s Message Commenting on the performance for Q4 & FY19, Mr. Rajendra Gogri – Chairman & MD at Aarti Industries Ltd. said, “During FY19, we have delivered another strong performance recording a significant milestone with consolidated revenue crossing Rs. 5,000 crore and strong profit growth d
Slide 9: Q4 FY19 Highlights
Q4 FY19 Highlights Financial & Capex Strong improvement in revenue and margins across Speciality Chemicals and Pharma segments EBIT margin expands 210 bps YoY to 16.1% in Q4 FY19 As part of its strategy to safeguard business against currency risks, the Company had entered into forward contract
Slide 10: Q4 & FY19 P&L (Standalone)
Q4 & FY19 P&L (Standalone) Y‐o‐Y Y‐o‐Y Particulars FY19 FY18 Growth Q4 FY19 Q4 FY18 Growth (Rs. Crore) (%) (%) Gross Income from Operations 4,857.6 3,699.3 31.3% 1,211.4 1,029.4 17.7% Exports 1,868.6 1,592.7 17.3% 496.9 400.7 24.0% % of Total Income 38.5% 43.1% ‐4.6% 41.0% 38.9% 2.1% • Expanding con
Slide 11: Q4 & FY19 – Speciality Chemicals (Standalone)
Q4 & FY19 – Speciality Chemicals (Standalone) Revenue 3822 2879 Volume growth of 3% in Q4 FY19 and 8% in 787 920 FY19 Higher EBIT on account of increasing share of Q4 FY18 Q4 FY19 FY18 FY19 value added and high margin products. EBIT margins expand to 21.8% in Q4 FY19 from 18.3% in Q4 FY18 EBIT
Slide 12: Q4 & FY19 – Pharma & HPC (Standalone)
Q4 & FY19 – Pharma & HPC (Standalone) Diversified contribution from domestic, regulated and non‐regulated markets Pharmaceuticals Revenue Pharmaceuticals EBIT 726 113 Focusing on off‐patented generics in regulated markets 556 79 Expanding business volumes across markets and operating leverage
Slide 13: FY19 P&L (Consolidated)
FY19 P&L (Consolidated) Y‐o‐Y Particulars FY19 FY18 Growth (Rs. Crore) (%) Gross Income from Operations 5,014.2 3,806.1 31.7% Exports 2,011.9 1,691.1 19.0% % of Total Income 40.1% 44.4% ‐3.3% • Expanding contribution of higher EBITDA 970.6 699.1 38.8% value products and geographic de‐ risking EBITDA
Slide 14: Revenue Performance (Consolidated)
Revenue Perfomance (Consolidated) Operating revenues have Revenue Export Deep engagement with CAGR: 15% 1,868 global customers in grown on the back of 1,523 1,596 1,449 1,431 Speciality chemicals and strong volume growth in 5,014 key business segments and 3,806 pharma. In addition, part 2,908 3,005
Slide 15: EBIT Performance (Consolidated)
EBIT Performance (Consolidated) EBIT CAGR: 21% Higher growth relative to 930 revenue highlights value 615 663 addition delivered by AIL 542 447 FY15 FY16 FY17 FY18 FY19 Speciality Chemicals Pharmacuticals Home & Personal Care CAGR: 19% 819 CAGR: 33% 3 3 113 566 581 79 1 504 408 39 48 36 (0) (2) FY15
Slide 16: Contact Us
Contact Us For further information please log on to www.aarti‐industries.com or contact: Mr. Chetan Gandhi / Mr. Raj Sarraf Aarti Industries Limited Tel: +91 22 6797 6666 Email: info@aarti‐industries.com Shiv Muttoo / Varun Divadkar CDR India Tel: +91 22 6645 1207/ 97637 02204 Email: shiv@cdr‐india.
Slide 17: Thank You
Thank You 16